Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

Multiple Sclerosis (MS) is a chronic inflammatory \& degenerative disease of the central nervous system (CNS) Recent data from the MS Base registry demonstrated an average delay of 152 - 215 days between first presentation and the diagnosis of MS, and more than one year until Disease Modifying Treatment (DMT) begins. Evidence suggests that shutting down inflammation using highly effective DMTs early after diagnosis leads to better long term clinical outcomes The AttackMS trial will test the effect of starting a highly-effective DMT licensed for MS, Tyruko® (Natalizumab 300mg), within a short time - 14 days - after symptom onset.

NCT Number	NCT05418010
Lead Sponsor	Queen Mary University of London Collaborators: Biogen, UCL Queen Square Institute of Neurology, Moorfields Eye Hospital NHS Foundation Trust, Barts & The London NHS Trust
Conditions	Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination
Enrollment	40 participants
Start Date	2022-12-01
Primary Completion	2027-10-31 (estimated)
Study Completion	2027-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-07